Kardigan (NASDAQ:KARD - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.
A number of other analysts have also issued reports on the company. Leerink Partners decreased their price objective on Kardigan from $37.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, November 13th. Cantor Fitzgerald began coverage on Kardigan in a report on Thursday, October 29th. They set an "overweight" rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. cut their target price on Kardigan from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Tuesday, August 25th. UBS Group started coverage on Kardigan in a research note on Monday, October 12th. They issued a "buy" rating and a $25.00 target price for the company. Finally, HC Wainwright assumed coverage on Kardigan in a report on Wednesday, November 4th. They set a "buy" rating and a $42.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kardigan currently has an average rating of "Moderate Buy" and an average price target of $41.00.
Get Our Latest Stock Report on KARD
Kardigan Stock Down 8.2%
Kardigan stock opened at $11.49 on Friday. The firm has a 50 day simple moving average of $14.40. Kardigan has a 1-year low of $11.49 and a 1-year high of $27.00.
Kardigan (NASDAQ:KARD - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.16. Sell-side analysts forecast that Kardigan will post -3.41 EPS for the current year.
Hedge Funds Weigh In On Kardigan
Institutional investors have recently added to or reduced their stakes in the business. New York State Common Retirement Fund purchased a new stake in shares of Kardigan in the 3rd quarter valued at about $145,000. Integral Health Asset Management LLC grew its holdings in shares of Kardigan by 12.5% during the third quarter. Integral Health Asset Management LLC now owns 225,000 shares of the company's stock worth $3,319,000 after purchasing an additional 25,000 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Kardigan during the third quarter worth about $304,000. State Street Corp purchased a new position in shares of Kardigan during the third quarter worth about $6,721,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Kardigan in the third quarter worth approximately $31,000.
About Kardigan
(
Get Free Report)
Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company's activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kardigan, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kardigan wasn't on the list.
While Kardigan currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.